Corcept Therapeutics Says Trial of Lifyorli Combination Slows Ovarian Cancer Growth

MT Newswires Live10-26

Corcept Therapeutics (CORT) said Monday that results from a mid-stage trial evaluating the combination of Lifyorli with nab-paclitaxel and bevacizumab showed the treatment slowed ovarian cancer progression and shrank tumors in patients.

The pharmaceutical company said the study demonstrated a median progression-free survival of 7.2 months and an objective response rate of 59% in 95 patients with platinum-resistant ovarian cancer.

Patients whose tumors return or resume growing less than six months after receiving platinum-containing therapy are deemed "platinum-resistant," Corcept said.

Shares of Corcept were up 2.5% in recent Thursday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment